Effect of obesity on biodistribution of nanoparticles by Felismino, Claudiana de Jesus et al.
 
Document downloaded from: 
 

























Felismino, CDJ.; Helal-Neto, E.; Portilho, F.; Rocha Pinto, S.; Sancenón Galarza, F.;
Martínez-Máñez, R.; Ferreira, ADA.... (10-0). Effect of obesity on biodistribution of
















Effect of Obesity on Biodistribution ofNanoparticles 
 
Claudiana de Jesus Felismino1, Edward Helal-Neto1, Filipe Leal Portilho1, Suyene 
Rocha Pinto1, Félix Sancenón2,3,4, Ramón Martínez-Máñez2,3,4, Agatha de Assis 
Ferreira5, Simone Vargas da Silva5, Thereza Christina Barja-Fidalgo5, Ralph 
Santos-Oliveira1,6 
 
1- Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de 
Janeiro, Brazil 
2- Instituto Interuniversitario de Investigación de Reconocimiento Molecular y 
Desarrollo Tecnológico (IDM), UniversitatPolitècnica de València, Universitat de 
València. Caminode Vera s/n, 46022, Valencia, Spain 
3- Departamento de Química, Universidad Politécnica de Valencia, Caminode 
Vera s/n, 46022, Valencia, Spain. 
4- CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). 
5- LaboratoryofCellularand Molecular Pharmacology; DepartmentofCellBiology, 
IBRAG, Universidade do Estado do Rio de Janeiro,RJ, Brazil 
6- Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Zona Oeste 
State University, Rio de Janeiro, Brazil 
All correspondence to 
Dr Ralph Santos-Oliveira 













































Nanoparticles have specific features (lipophilicity, surface charge, composition and 
size). Studies regarding the biological behavior of nanoparticles in diseases such 
diabetics and obesity are scarce. Here, we evaluated two nanoparticles: magnetic 
core mesoporous silica (MSN) (58nm) and polycaprolactone (PCL) nanoparticle 
(280nm) in obese mice. Changes in the biodistribution were observed, especially 
considering the mononuclear phagocyte system (MPS), and the visceral fat tissue. 
Nonetheless, our data corroborates the influence of size in the biodistribution in 
obese animals, supporting that smaller nanoparticles, may show a higher tissue 
deposition at spleen, due the associated splenomegaly and the complications 
arising from this state. Finally, our study demonstrated that, in obesity, probably 
due the low-grade inflammatory state associated with metabolic syndrome a 
difference in accumulation of nanoparticles wasfound, with profound impact in the 
tissue deposition of nanoparticles.  
























Overweight and obesity can be defined as an accumulation of abnormal or 
excessive body fat, which can be harmful to health. In accordance to the World 
Health Organization (WHO) the number of obese people in the world more than 
doubled since the 1980s, and is considered, since 1975 as a chronic disease [1]. 
Also, obesity has a strong link with several co-morbidities, especially the type 2 
diabetes mellitus[2].  
The increased content of fat, in contrast to a low percentage of lean tissue 
and water, besides several physiopathological modifications often associated to 
obesity, may affect drugbiodistributionand elimination. In these individuals, the 
blood flows per gram of fat is lower than in nonobese, and histological hepatic 
alterations are usually associated to markedly alteration in the RES 
(Reticuloendothelial System). Furthermore, obese patients present a higher 
glomerular filtration rate and, consequently, a differentiated volume of distribution, 
with serious implication in loading-dose parameter[2-6]. 
In general, the use of nanoparticles associated with cosmetic formulations 
and as drug itself is increasing globally. Accordingly the FDA (Food and Drug 
Administration) approved over 350[7]nanodrugs that are already available in 
market, among them liposomes are the most commonly used nanostructures, 
followed by nanocrystals and over 7.000 nano-based products were 
commercialized in the last years. Because of the physicochemical properties that 
make the nanomaterials suitable for bio tagging or targeting, different approaches 














Since the use of nanodrugs is rapidly increasing worldwide, more 
information must be acquired, especially at specific strata of the population as 
obese. In this scenario we evaluated the biodistribution and tissue deposition of 
two nanomaterials: i) magnetic core mesoporous silica and ii) polymeric 
nanoparticles, in order to understand the changes caused by the obesity. The 
choice of these two systems was based on the structural differences between 
both, especially size, surface area and physicochemical properties.  
 
MATERIALS AND METHODS 
 
Preparation of Magnetic Core Mesoporous Silica Nanoparticles 
Reagents and Materials 
Iron (III) chloride hexahydrate, iron (II) tetrachloride hexahydrate, oleic acid, 
hexadecyltrimethylammonium bromide (CTAB) and tetraethyl orthosilicate (TEOS) 
were purchased form Sigma. Ammonia solution (32%), ethanol and ethyl acetate 
were purchased from Scharlau. Chloroform was obtained from Acros Organics. 
Distilled water was used in all reactions. 
 
Synthesis of oleate-coated iron oxide nanoparticles  
Iron oxide nanoparticles (Fe3O4 magnetite nanocrystals) were obtained by a 
modified coprecipiationmethod[9]. Briefly, 12 g of iron (III) chloride hexahydrate 
were mixed with 4.9 g of iron (II) chloride tetrahydrate in 50 ml of water at 80 ºC 














was carefully added and the mixture turned completely dark. Oleic acid (2.13 ml) 
was added after 30 min and the reaction was left stirring at 80 ºC for another 90 
min. The reaction was cooled down and centrifuged at 9500 rpm during 10 min. 
The resulting black precipitate was washed three times with distilled water and 
three times with ethanol and then dried under vacuum overnight. In order to 
prevent their oxidation, the oleate-coated iron oxide nanoparticles were kept in 
chloroform giving a dark brown ferrofluid. 
 
Synthesis of magnetic core MSNs 
In a typical procedure, 100 mg of CTAB were dissolved in 10 ml of water, 
followed by addition of 0.74 ml of the ferrofluid (8.88 mg/ml). The mixture was 
placed in a probe sonicator (Branson 450 Sonifier) for 2 min, giving an oil-in-water 
emulsion. Then, the mixture was heated to 65 ºC to evaporate the chloroform and 
achieve an effective phase transfer from chloroform to water. The resulting 
transparent aqueous suspension was added to a solution of 30 ml of water and 
0.548 ml of ammonia (32%), which was then, heated up to 75 ºC. Then, 0.5 ml of 
tetraethyl orthosilicate (TEOS) was added dropwise followed by addition of 3 ml of 
ethyl acetate. The reaction was stirred at 350 rpm and 75 ºC during 3 h. Then, the 
reaction was placed on an ice bath and the nanoparticles were collected by 
centrifugation (9500 rpm, 10 min). Afterward, the sample was washed with ethanol 
twice and dried under vacuum overnight. The final magnetic core MSNs were 
















Characterization of magnetic core MSNs 
Powder X-ray Diffraction 
The synthesised materials were characterised by powder X-ray diffraction 
(PXRD), transmission electron microscopy (TEM) and N2 adsorption-desorption 
analysis. PXRD measurements were obtained using a Bruker AXS D8 Advance 
diffractometer equipped with CuKα radiation and working at 40 kV/40 mA. PXRD 
measurements were performed at high angle (2θ = 15°- 68°) and low angle range 
(2θ = 1.3°- 8.3°). 
 
Transmission Electron Microscopy 
TEM images were taken on a 100 kV JEOL JEM-1010 microscope operated 
with AMT image capture engine software. TEM samples were prepared by adding 
10 µl of nanoparticles suspended in distilled water onto carbon-coated copper 
grids. The statistical analysis of the data obtained from TEM images was 
performed using Origin Pro software. 
 
N2 adsorption-desorption 
N2 adsorption-desorption measurements were conducted in a TriStar II Plus 
surface area and porosity analyzer from Micromeritics. The specific surface area of 
the material was determined from the adsorption-desorption isotherm by applying 
the BET model. The pore volume and average pore size was estimated by using 
the BJH model. 
 














Development of Ethambutol Nanoparticle  
To the nanoparticles preparation, an ethambutol tablet (400 mg of 
ethambutol hydrochloride, oral administration) was triturated and then an amount 
containing 5 mg of ethambutol was weighted (which represents 10% of the polymer 
mass to be added to the nanoparticle) and solubilized in 0.1 wt% PVA aqueous 
solution. 
Ethambutol nanoparticles were preparedby double emulsion solvent 
evaporation method where 200 µL of ethambutol-PVA aqueous solution was 
dripped into 2 mL of dichloromethane, where 50 mg of PCL (with a molar mass of 
42000 g/mol) were previously solubilized and then sonicated (UP100H, Hielscher) 
for 1 minute at 55W to produce a water-in-oil emulsion.This emulsion was 
emulsified again with 4 mL of PVA 1 wt% solution by ultrasound processing for 2 
min (55W) to produce a W/O/W emulsion.  
Then dichloromethane was evaporated under reduced pressure during 1 
hour at 25°C. PCL-NPs were recovered by centrifugation (20,000 rpm for 20 min) 
and washed twice with distilled water to remove the excess of PVA. At the end only 
PCL- ethambutol nanoparticles were used.  
Size determination by DLS 
Nanoparticles size distribution, mean size and polydispersity index (PDI) of 
the ethambutol nanoparticle were determined by dynamic light scattering (DLS) 
using the equipment Zetasizer Nano ZS (Malvern Instruments, UK). Measurements 














sample was 173º using a 12 mm2 quartz cuvette. The mean ± standard deviation 
(SD) was assessed. 
 
Scanning Electron Microscopy (SEM)  
The morphology of nanoparticles was examined by Scanning Electron 
Microscopy (SEM) (TM 3000 – Hitachi), with a tension varying from 10 to 20 kV. The 
sample, 10µL of the nanoparticle solution, was fixed on a carbon tape and dried under 
aseptic conditions.   
 
Labeling Process with 99mTc 
The labeling process was done by the direct radiolabeling process as 
described previously [10,11]. In this methodology we used 150 µg of each 
nanoparticle: i) Magnetic Core Mesoporous Silica Nanoparticles, ii) ethambutol 
polymeric nanoparticle. Briefly, 100 µCi (approximately 300 µL) of 99mTc was 
incubated with a stannous chloride (SnCl2) solutions (80 µg/mL) (Sigma-Aldrich) for 
20 minutes at room temperature. Then this solution was incubated with 150 µg of 
each nanoparticle (Magnetic Core Mesoporous Silica Nanoparticles and 
Ethambutol Polymeric Nanoparticles) for another 10 minutes in order to label their 
structures. 
 
Quality Control of the Labeling Process with 99mTc 
In order to confirm the efficacy of the labeling process with the nanoparticles 
was performed a paper chromatography using Whatman paper nº 1. In this 














mobile phase. The radioactivity of the strips was verified in a γ-counter (Perkin 
Elmer Wizard® 2470, Shelton, CT City, State). 
 
In vivo Analysis 
Animals and high fat diet (HFD) protocol 
All experiments on animals were conducted according to the principles of 
NIH Guide for the Care and Use of Laboratory Animals and were approved by the 
Committee for the Ethics of Animal Experimentation of the Universidade do 
Estado do Rio de Janeiro (Permit number: CEA/024/2017). 
Male C57BL/6 mice (n=12) were obtained from Federal University of Rio de 
Janeiro (UFRJ, Rio de Janeiro, Brazil) at 3 weeks of age. After 1 week of 
adaptation, the animals were housed separate cages and were fed either regular 
chow (C; 396 Kcal/100 g, 13% of energy derived from fat) or a High Fat Diet 
(HFD, 470 Kcal/100 g, 45% of energy derived from fat) for 10 weeks in a 
temperature-controlled room (25±1°C), with 60% humidity and 12-hours artificial 
light-dark cycle. Body weight was measured throughout the treatment period. 
 
Body composition analysis  
Body composition analysis was performed by nuclear magnetic resonance. 
Briefly, mice were scanned using the body composition analyzer for small animals 
(Bruker's Minispec LF90 TD-NMR, Massachusetts, USA). The instrument was 
calibrated for these studies using NMR scans and chemical composition data from 














of internal voltages, temperature, magnets, and NMR parameters was performed 
using a standard provided by the manufacturer. Animals were placed in a clear, 
plastic cylinder (50 mm diameter) and kept immobile by insertion of a tight fitting 
plunger into the cylinder (without having to anesthetize them). The tube was then 
lowered into the sample chamber of the instrument for approximately 2 minutes, 
the duration of the scan. 
 
Intraperitoneal glucose tolerance test (ipGTT) 
Mice were fasted for 12 hours and basal glucose was measured. Mice 
were then administered an i.p. bolus of glucose (2.0g/kg body weight) and 
glycemia was monitored every 30 minutes for up to 120 minutes. Glycemia was 
measured with an Accu Check Active glucometer (Roche diagnostics, Mannheim, 
Germany). 
 
Intraperitoneal insulin tolerance test (ipITT) 
Mice were weighted and fasting blood glucose levels were measured. Mice 
were then administered an i.p. injection of insulin (0.1 U/mL; Humulin human 
insulin; Eli Lilly, São Paulo, Brazil) resulting in a dose of 0.5 U/kg. Blood glucose 
was measured at 15, 30, 45, 60, and 120 min after injection. 
 
Biodistribution 
The mice were maintained under controlled temperature (23ºC ± 2) with 
water and food ad libitum. No anesthetic was used. The labeled samples (3.7 














in table 1.  After 24 hours of drug administration, the mice were sacrificed by 
asphyxiation (CO2chamber) and then dissected and their lungs were removed, 
weighed and the radioactivity uptake counted in a gamma counter (Perkin Elmer). 
Results were expressed as percentage of injected dose per gram of tissue. The 
Institutional Review Board and the Animal Ethics Committee approved the study 
protocol.  
 
Table 1: Distribution of number of animals (n) used for the biodistribution study with 
radiolabeled nanoparticles (magnetic core mesoporous silica and polycaprolactone 
ethambutol) into the two groups:  obese and nonobese (lean) mice. 
 










The data were expressed as means standard error and analyzed by the two-
tailed unpaired Student’s t test. When appropriate, individual comparisons were 














considered statistically significant when p<0.05. The data were analyzed using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, USA). 
 
RESULTS & DISCUSSION 
Magnetic Core Mesoporous Silica 
Characterization of Magnetic Core MSNs  
The structure periodicity of the mesoporous material was confirmed by 
PXRD, which showed a sharp peak at the low-angle region for both as-made (S0-
1) and calcined (S0-2) magnetic core MSNs (Figure 1). The slight shift of the peak 
to higher angles indicates a shrinkage of the silica matrix due to the condensation 
of silanol groups during the calcination process. PXRD analysis at high angles 
















Figure 1.X-ray diffraction analysis of the magnetic core MSNs (S0-1) and calcined 
magnetic core MSNs (S0-2),  showing the magnetite nanocrystals and the 
characteristic broad peak of amorphous silica. 
The mesoporous structure of S0-2 magnetic core MSNs was also analysed 
by transmission electron microscopy and the size of the primary nanoparticles was 
determined by image analysis (58.9 ± 8.1 nm, n = 100). The data was represented 
in a histogram, which shows the particle size distribution of the S0-2 nanoparticles 
(Figure 2).  
 
Figure 2. A: Transmission Electron Microscopy (TEM) images magnetic core 
mesoporous silicananoparticles. B: Size histogram and normal size distribution of 
magnetic core mesoporous silica nanoparticles, corroborating the size of 58nm. 
 
The N2 adsorption-desorption isotherms of the magnetic core MSNs 
presented a typical type IV behaviour (Figure 3), characteristic of mesoporous 
materials. From the isotherm curve, a specific surface area of 872 m2/g was 

















Figure 3.N2 adsorption-desorption analysis showing the pore size distribution of 
the magnetic core mesoporous silica nanoparticles, corroborating the pore size of 
3.15nm. 
 
Ethambutol Polymeric Nanoparticle 
The results from SEM (figure 4) showed that nanoparticles size was about 
280-300nm. A late SEM image demonstrated that nanoparticles may aggregate, 

















Figure 4-Scanning Electron Microscopy imaging, performed immediately after 
the production of the polymeric ethambutol nanoparticle showing nanoparticle with 
a range of size about 280-320nm. 
 
Figure 5: Scanning Electron Microscopy imaging, performed after 10 days of 

















Thus, considering the circumference volume (Cv) equation,  
       
Where: Cv: circumference volume 
Π: constant pi 
R: Radius of the circumference 
 
The molar mass of PCl: 66.4268 g/mol. As also the medium average size of 
the ethambutol nanoparticle of 290nm, we have that the weight of one single 
ethambutol nanoparticle is about: 3,6x10-15g. 
 
DLS Size Characterization 
Figure 6 shows the mean size and size distribution of the ethambutol 
nanoparticles. According to the distribution profile it is possible to infer that 
nanoparticles presented a monomodal size distribution, with a mean size of 270 
nm, corroborating the findings of SEM. The narrow peak suggests a homogeneous 
system with sizes near to the mean. According to Paranjpe and Müller-Goymann 
(2014)[12] particles smaller than 500 nm deposited in the alveolar region, it could 
sediment be retained in the bronchiolar region for a longer time when compared to 















Figure 6 - Dynamic light scattering analysis (DLS) showing the mean size and size 
distribution of the polycaprolactoneethambutol nanoparticles, corroborating a 
monomodal size distribution, with a mean size of 270 nm. 
 
Labeling with 99mTc 
The magnetic core mesoporous silica nanoparticles were successfully 
labeled with 99mTc, showing an average of labeling efficacy over 98%. A similar 
result was found for the polymeric ethambutol nanoparticle which had a labeling 
efficacy of 99% 
 
Quality Control 
The stability of the labeling process from the ethambutol polymeric 
nanoparticles and magnetic core mesoporous silica nanoparticles with the 99mTc 














Table 2: Percentage of labeled ethambutol polymeric nanoparticles with 
99mTcobserved over time (4 hours). 
 
Time (h) Labeling (%) 
0 99,52±1,2 
1 99.45 ± 1,3 
2 99,55± 1,0 
4 99,21 ± 1,1 
 
Table 3: Percentage of labeled Magnetic Core Mesoporous Silica Nanoparticles 
with 99mTc  observed over time (4 hours). 
 
Time (h) 
Labeling (%) Magnetic Core Mesoporous Silica 
Nanoparticles  
0 99.6± 0.7% 
1 98.8± 0.5% 
2 99.3± 1.0% 
4 98.0± 0.8% 
 
 
Animals and high fat diet (HFD) protocol 
As observed by the body composition analysis in figures (7A, 7B and 7C), 
animals reached the obesity state that is characterized by increased body mass, 














reduction in glucose uptake, that has been confirmed by the ipGTT corroborating 









Figure 7: Body composition analysis with both groups under study (obese e 
nonobese) showing the  alteration that all the animals reached in the obese group, 
as high increase in the body mass (A), decrease in the lean mass (B) and increase 
in fat mass (C).The results are shown as the mean ±SE calculated from 3 different 
animals *p<0.05 and **p<0.001 when compared to nonobese mice. 
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Figure 8:Comparison of Intraperitoneal insulin tolerance test (ipITT) (A) and 
intraperitoneal glucose tolerance test (ipGTT) (B) in both groups (obese and 
nonobese) shows the increase on insulin tolerance in the obese group with no 
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To address the interference of obesity on the biodistribution of polymeric 
nanoparticles (figure 9) and magnetic core mesoporous silica (figure 10), particles 
were injected (i.o.) in different groups of obese and non-obese mice. The 
distribution in the liver and spleen of obese and nonobese mice of the polymeric 
nanoparticles 24 h after its administrationis shown in Table 4. 
Data indicates that a statistical difference between the two groups were 
detected in the distribution of polymeric nanoparticles in liver/spleen (∑), obese 
animals showed an apparent lower uptaking capacity (78,5%), compared to 
nonobese mice (92,04%), considering the total nanoparticles administered. 
Nevertheless, call attention the fact that spleens and liver of obese mice 
accumulated less nanoparticles (9,03% and 69,47%respectively) than nonobese 
(12,49% and 79,55%, respectively). 
 
Table 4: Evaluation on the  uptake of ethambutol polymeric nanoparticles in liver 
and spleeninto the two groups (obese and nonobese). 
  










Liver 3,22(±0,04) 3,66(±0,008)* 69,47 79,55 
Spleen 0,419(±0,003) 0,575(±0,003)*** 9,03 12,49 
 
The results are shown as the mean ±SE calculated from 3 different animals. 














Several studies on biodistribution of nanoparticles have shown that they can 
be highly uptaken(from 30% to 99%)by liver and spleen[13;14], two organs with an 
active mononuclear phagocyte system (MPS).This systemworks, particularly in 
spleen, lymphonodes and liver, as an immune network to remove foreign material 
and pathogens from the bloodstream[15-17]. In the liver, although Kupffer cells, have 
been consideredthe main responsible for phagocytic activity [18],recent studies 
suggested that other cells in thehepatic inflammatory microenvironment should be 
considered for nanoparticlessequestration[17,19]. 
Obesity has been characterized as a low-grade inflamed sub-acutestate, 
characterized by a chronic infiltration of macrophages in adipose tissue, which in 
turn mediates local and systemic inflammation and acts as a key contributor to 
insulin resistance[20]. Adipose tissue macrophagesare derived largely from 
circulating monocytes stimulated by inflammatory mediators released by the obese 
adipose tissue[21-23],and may contribute, as a classical MPS organ, to 
nanoparticlesuptake by the obese adipose tissue.Furthermore, considering that in 
obese mice the abdominal region is more distended, this may cause an increase in 
vessel diameter, augmenting vessels fenestration and volume, consequently 
increasing the perfusion volume [24-27]. In agreement, as shown in Table 5, a higher 
uptake of nanoparticles by the epidydimal and abdominal fat tissue in obese mice 


















Table 5: Evaluation on the uptake of ethambutol polymeric nanoparticles by the fat 
tissue in obese and nonobese animals 
 
  
%uCi uptake  




Epididymal fat 0,01(±0,0004) 0,003(±0,00006)* 
Abdominal fat 0,036(±0,0008) 0,0083(±0,00005)*** 
 
The results are shown as the mean ±SE calculated from 3 different animals 
*p<0.05 and **p<0.001 when compared to nonobese mice. 
 
As can be observed in the fat tissue, occurred an increased ratio of 2.77-fold 
(0,0460/0,00136) higher uptake in obese when compared to nonobese (Table 5). 
Although the uptake by the adipose tissue respondedfor less than 2% of the total 
amount of nanoparticles injected in the animals, is important to emphasize that the 
inflamed condition in obesity may contribute to increase the uptake of 
nanoparticles by the obese adipose tissue.The obese state in our model, also 
contributes for an increased uptake by stomach and intestines (Figure 9), and fat 
accumulation in these organs justifies the results. Visceral adipositycaninducethe 
production of pro-inflammatory mediators and immune-cell infiltration, contributing 
to the low-grade systemic inflammation, resulting in macrophage 
accumulation/migration, insulin resistance and metabolic syndrome, and 














A discrete but higher uptake by pancreas was observed in obese 
mice(Figure 9). During obesity, the pancreatic functions are rather overwhelmed. 
This highly-activated state in obese mice is subsidized mainly by the accumulated 
peri-pancreaticadipose tissue, allowinga higher uptake by the organ [33,34].,  
The metabolic alterations in obesity can dramaticallyaffect the 
cardiovascular and pulmonary system.  Obese individuals often present distension 
of the thoracic-abdominal region that can lead to limited diaphragm mobility and rib 
movement. Nonetheless, the excess of adipose tissue may also lead to lung 
hypodevelopment[35], with alterations inbronchial responsiveness, and risk of 
asthma. Because of that, obese individuals tend to present higher respiratory rates 
and lower tidal volume[36,37]. All these factorsmayexplain the higher uptake of 
nanoparticles by lungs (right and left) ofobesemice, when compared tononobese.  
 
 
Figure 9: Biodistribution of 99mTc labeled ethambutol polymeric nanoparticles in 






















ethambutol polymeric nanoparticles in liver and spleen these both data has been 
removed in order to better understand the behavior in the other organs. 
 
The biodistribution of the magnetic core mesoporous silica, have shown to 
be very much alike to that of the polymeric nanoparticle of ethambutol, and there 
was no great change between obese and nonobese mice in the total body 
distribution (figure 10). 
The results from biodistribution of magnetic core mesoporous silica 
nanoparticles showed no difference in uptake by the liver in both cases: obese and 
nonobese mice. On the other hand a great difference of over 33-fold higher uptake 
in spleen by obese mice was observed, as demonstrated in table 6: 
 
Table 6: Evaluation on the uptake of magnetic core mesoporous silica 
nanoparticles by the liver and spleen in obese and nonobese mice. 
  










Liver 0,12(±0,006) 0,01(±0,0003)* 33,64 27,94 
Spleen 0,099(±0,0002)* 0,003(±0,00002)*** 26,94 8,31 
 
The results are shown as the mean ±SE calculated from 3 different animals 
*p<0.05 and **p<0.001 when compared to nonobese mice. 
The great difference of uptake in spleen between obese and nonobese mice in the 














obesity a splenomegaly via sinusoidal dilatation and intra-cellular or intercellular 
deposits is observed. The splenomegaly, increases the discontinuous gaps at 
endothelium, which lines the sinusoidal walls spleen, allowing the passive 
entrapment of foreign particulates[38,39], especially the ones with small size, as the 
magnetic core mesoporous silica (58nm). For that reason, a higher uptake of 
magnetic core mesoporous silica nanoparticles in spleen was observed in obese 
mice than in nonobese.  
An important fact that our data showed is regarding the facilitated interaction 
between mesoporous silica and macrophages.  According to the literature, due the 
large surface area of the mesoporous silica nanoparticles, the interaction between 
macrophages and magnetic core mesoporous silica, should be facilitate, leading to 
their rapid recognition by the MPS, and fast clearance by RES, especially in obese 
mice, which the MPS is highly activated[40,41]. In contrast, polymeric agents(as the 
polycaprolactone, used in the ethambutol nanoparticles) tend to create a steric 
hindrance and repulsion effect of polymeric chains against blood proteins and 
macrophages[42], resulting in a “protective” effect making this system less prone to 
the action of the MPS. In our study we found exactly the opposite of the literature. 
We had a high recognition by the MPS of polymeric nanoparticles (∑78,5% and 
∑92,04%), respectively obese and nonobese mice. While the magnetic core 
mesoporous silica nanoparticles showed ahalved uptake by the MPS (∑ 60,58% 
and ∑ 36,25%) obese and nonobese mice, respectively.  The most accepted 
explanation is due the size, where bigger nanoparticles are more likely to be 
recognized by the MPS[43-45]. Then, indifferent to surface features, size outweighs 
















Figure 10: Biodistribution of 99mTc labeled magnetic core mesoporous silica 
nanoparticles in obese (purple) and nonobese (green) mice. Due the high uptake 
of the 99mTc labeled ethambutol polymeric nanoparticles in liver and spleen 
these both data has been removed in order to better understand the behavior in 
the other organs 
 
 
Table 7: Evaluation on the uptake of magnetic core mesoporous silica nanoparticle 
by the fat tissue in obese and nonobese animals. 
 
Organ %uCi uptake Obese %uCi uptake Nonobese 
Epididymal fat 0,0024(±0,00006) 0,00082(±0,00004)*** 























The results are shown as the mean ±SE calculated from 3 different animals 
*p<0.05 and **p<0.001 when compared to nonobese mice. 
 
It is important to notice that a higher uptake in fat tissue was observed for 
the magnetic core mesoporous silica, with a ratio of 2.44-fold 
(0,004uCi/0,00164uCi) higher uptake in obese related to nonobese (table 7). 
Almost the same ratio found in the polymeric nanoparticles. This data confirm the 
participation of the MPS in the whole of biodistribution of nanoparticles. 
 
CONCLUSION 
Our data demonstrated that obesity can interfere in the biodistribution of 
nanoparticles, with participation of the fat tissue. The exactly mechanism involved 
and responsible for these changes must be elucidated in order to promote the 
safety use of nanoparticles in different population strata.  
Also, our findings suggest that, probably, due the low-grade inflammatory 
state, leading to a metabolic syndrome, observed in obesity, a critical paradigm 
shift can be observed. In general, the literature subsidizes that very small (15<nm) 
nanoparticles are filtered by the kidney; nanoparticleslarger than 15 nm and 
smaller than 200 nm are captured by Kupffer cells and splenic marginal zone 
macrophages, whereas particles larger than 200 nm are retained in the red pulp of 
the spleen. Our data showed that in obesity the opposite occurs. We had bigger 
nanoparticles (280nm) higher uptaken by the liver (Kupffer cells), whereas smaller 














Nonetheless, our data suggest that regardless the surface characteristics, 
the nanoparticles size seems to have a predominant effect, especially regarding 
the spleen uptake , which under specific conditions (splenomegaly) tends to be 
more permeable to smaller nanoparticles. 
Other studies using different nanoparticles such as Au-nanoparticles, PLA-
nanoparticle, SBA-15 mesoporous silica nanoparticles and Spions,should be 
performed in order to corroborate our findings and ensure the interference of 
obesity in the processes related to normal biodistribution of nanoparticles. 
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